Anacor Pharmaceuticals (ANAC) 15.51 $ANAC
Anacor Pharma Remains Over-Valued on Development of Inferior Drugs
at The Street - Wed Apr 16, 7:00AM CDT
Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 10, 12:34PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Healthcare Companies Report Regulatory Affirmations, MPA Inspections, Enrollment in Trials, Stock Movements - Analyst Notes on Halozyme, Align Technology, Cambrex, Receptos, and Anacor Pharmaceuticals
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), Align Technology Inc. (NASDAQ: ALGN), Cambrex Corporation. (NYSE: CBM), Receptos, Inc. (NASDAQ: RCPT), and Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Anacor Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 5:50PM CDT
Anacor Pharma enrolled the first patient in a phase III study on its atopic dermatitis candidate, AN2728, for the topical treatment of mild-to-moderate atopic dermatitis
Anacor Pharmaceuticals admits first patient in Phase 3 trial of AN2728 in mild-to-moderate atopic dermatitis
M2 - Mon Mar 31, 4:20AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) said on Monday that it has enrolled the first atopic dermatitis subject under its Phase 3 trial of AN2728.
Anacor Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial of AN2728 in Mild-to-Moderate Atopic Dermatitis
Business Wire - Sun Mar 30, 11:30PM CDT
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children.
Insider Trading Alert - ANAC, N And PRAA Traded By Insiders
at The Street - Tue Mar 25, 9:45AM CDT
Stocks with insider trader activity include ANAC, N and PRAA
Is Now a Good Time to Sell Anacor Pharmaceuticals, Inc.?
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 5:30PM CDT
Not many stocks can boast of rising more than 450% in a single year. And when they do, it's generally a good idea to take profits. That said, biotechs that are on the cusp of transitioning from a developmental-stage company into a commercial...
Supply Agreements, Patents, Appointments, and FDA Clearances - Analyst Notes on OPKO, Synageva, Hill-Rom, Anacor, and Cardiovascular Systems
PR Newswire - Thu Mar 20, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding OPKO Health, Inc. (NYSE: OPK), Synageva BioPharma Corp. (NASDAQ: GEVA), Hill-Rom Holdings, Inc. (NYSE: HRC), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), and Cardiovascular Systems Inc. (NASDAQ: CSII). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Anacor Pharmaceuticals Appoints Paul L. Berns as Chief Executive Officer
Business Wire - Wed Mar 19, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that the Company's Board of Directors has appointed Paul L. Berns, Anacor's Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately. Mr. Berns succeeds David P. Perry who has served as Anacor's President and Chief Executive Officer since 2002.
Anacor Pharmaceuticals Reports 2013 Fourth Quarter and Year-End Financial Results
Business Wire - Thu Mar 13, 3:01PM CDT
Anacor Pharmaceuticals (NASDAQ:ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2013.
Anacor Pharmaceuticals elects Vince Ippolito as EVP
M2 - Tue Mar 11, 3:16AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (ANAC) reported on Monday the addition of Vince Ippolito as its executive vice president and chief commercial officer.
Anacor Pharmaceuticals Announces Appointment of Vince Ippolito as Chief Commercial Officer
Business Wire - Mon Mar 10, 7:30AM CDT
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today the appointment of Vince Ippolito as Executive Vice President and Chief Commercial Officer. Mr. Ippolito has over 25 years of experience leading specialty medical sales and marketing efforts at Valeant Pharmaceuticals, Inc. (Valeant), Medicis Pharmaceutical Corporation (Medicis) and Novartis AG.
Anacor Pharmaceuticals Announces 2013 Fourth Quarter and Year End Financial Results Conference Call and Webcast
Business Wire - Thu Mar 06, 3:30PM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the fourth quarter and year ended December 31, 2013 on Thursday, March 13, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com and will be available for three months following the call.
Update on Anacor's AN2728 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:50PM CST
Anacor successfully completed an end-of-phase II meeting with the FDA regarding its atopic dermatitis candidate, AN2728
Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the Treatment of Mild-to-Moderate Atopic Dermatitis With AN2728
Business Wire - Thu Feb 27, 6:36AM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) for the topical treatment of mild-to-moderate atopic dermatitis with AN2728 Ointment, 2%, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects 10% - 20% of infants and young children.
Anacor Pharmaceuticals to Present at the Cowen & Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 3:00PM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Geoff Parker, the company's Chief Financial Officer, will provide a company overview at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 3:30 p.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
NuScale Power Successfully Completes Helical Coil Steam Generator Testing Activities
Business Wire - Tue Feb 25, 7:02AM CST
NuScale Power, LLC announced today that it recently successfully completed its helical coil steam generator (HCSG) testing activities at the SIET S.p.A. (SIET) facilities in Piacenza, Italy, and that during that same time period, the U.S. Nuclear Regulatory Commission (NRC) conducted a successful quality assurance (QA) inspection of the testing activities. The result of the inspection was a rare outcome in that the NRC concluded with no findings, observations, violations, recommendations or non-conformances identified.
Contact Dermatitis - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxk6vr/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2013" report to their offering. 'Contact Dermatitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contact Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contact Dermatitis. Scope - A snapshot of the global therapeutic scenario for Contact Dermatitis. - A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contact Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Contact Dermatitis Overview Therapeutics Development Pipeline Products for Contact Dermatitis - Overview Pipeline Products for Contact Dermatitis - Comparative Analysis Contact Dermatitis - Therapeutics under Development by Companies Contact Dermatitis - Pipeline Products Glance Clinical Stage Products Early Stage Products Contact Dermatitis - Products under Development by Companies Contact Dermatitis - Companies Involved in Therapeutics Development Contact Dermatitis - Therapeutics Assessment Drug Profiles MRX-6 - Drug Profile RTU-1096 - Drug Profile MAM-06.301 - Drug Profile AN-3485 - Drug Profile HPT-721 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned R-Tech Ueno, Ltd. Marinomed Biotechnologie GmbH Anacor Pharmaceuticals, Inc. Celsus Therapeutics Plc Hapten Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/hxk6vr/contact About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Anacor Pharma Remains Over-Valued on Development of Inferior Drugs
at The Street - Wed Apr 16, 7:00AM CDT
Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 10, 12:34PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Healthcare Companies Report Regulatory Affirmations, MPA Inspections, Enrollment in Trials, Stock Movements - Analyst Notes on Halozyme, Align Technology, Cambrex, Receptos, and Anacor Pharmaceuticals
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), Align Technology Inc. (NASDAQ: ALGN), Cambrex Corporation. (NYSE: CBM), Receptos, Inc. (NASDAQ: RCPT), and Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Anacor Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 5:50PM CDT
Anacor Pharma enrolled the first patient in a phase III study on its atopic dermatitis candidate, AN2728, for the topical treatment of mild-to-moderate atopic dermatitis
Anacor Pharmaceuticals admits first patient in Phase 3 trial of AN2728 in mild-to-moderate atopic dermatitis
M2 - Mon Mar 31, 4:20AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) said on Monday that it has enrolled the first atopic dermatitis subject under its Phase 3 trial of AN2728.
Anacor Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial of AN2728 in Mild-to-Moderate Atopic Dermatitis
Business Wire - Sun Mar 30, 11:30PM CDT
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children.
Insider Trading Alert - ANAC, N And PRAA Traded By Insiders
at The Street - Tue Mar 25, 9:45AM CDT
Stocks with insider trader activity include ANAC, N and PRAA
Is Now a Good Time to Sell Anacor Pharmaceuticals, Inc.?
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 5:30PM CDT
Not many stocks can boast of rising more than 450% in a single year. And when they do, it's generally a good idea to take profits. That said, biotechs that are on the cusp of transitioning from a developmental-stage company into a commercial...
Supply Agreements, Patents, Appointments, and FDA Clearances - Analyst Notes on OPKO, Synageva, Hill-Rom, Anacor, and Cardiovascular Systems
PR Newswire - Thu Mar 20, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding OPKO Health, Inc. (NYSE: OPK), Synageva BioPharma Corp. (NASDAQ: GEVA), Hill-Rom Holdings, Inc. (NYSE: HRC), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), and Cardiovascular Systems Inc. (NASDAQ: CSII). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Anacor Pharmaceuticals Appoints Paul L. Berns as Chief Executive Officer
Business Wire - Wed Mar 19, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that the Company's Board of Directors has appointed Paul L. Berns, Anacor's Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately. Mr. Berns succeeds David P. Perry who has served as Anacor's President and Chief Executive Officer since 2002.
Anacor Pharmaceuticals Reports 2013 Fourth Quarter and Year-End Financial Results
Business Wire - Thu Mar 13, 3:01PM CDT
Anacor Pharmaceuticals (NASDAQ:ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2013.
Anacor Pharmaceuticals elects Vince Ippolito as EVP
M2 - Tue Mar 11, 3:16AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (ANAC) reported on Monday the addition of Vince Ippolito as its executive vice president and chief commercial officer.
Anacor Pharmaceuticals Announces Appointment of Vince Ippolito as Chief Commercial Officer
Business Wire - Mon Mar 10, 7:30AM CDT
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today the appointment of Vince Ippolito as Executive Vice President and Chief Commercial Officer. Mr. Ippolito has over 25 years of experience leading specialty medical sales and marketing efforts at Valeant Pharmaceuticals, Inc. (Valeant), Medicis Pharmaceutical Corporation (Medicis) and Novartis AG.
Anacor Pharmaceuticals Announces 2013 Fourth Quarter and Year End Financial Results Conference Call and Webcast
Business Wire - Thu Mar 06, 3:30PM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the fourth quarter and year ended December 31, 2013 on Thursday, March 13, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com and will be available for three months following the call.
Update on Anacor's AN2728 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:50PM CST
Anacor successfully completed an end-of-phase II meeting with the FDA regarding its atopic dermatitis candidate, AN2728
Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the Treatment of Mild-to-Moderate Atopic Dermatitis With AN2728
Business Wire - Thu Feb 27, 6:36AM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) for the topical treatment of mild-to-moderate atopic dermatitis with AN2728 Ointment, 2%, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects 10% - 20% of infants and young children.
Anacor Pharmaceuticals to Present at the Cowen & Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 3:00PM CST
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Geoff Parker, the company's Chief Financial Officer, will provide a company overview at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 3:30 p.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
NuScale Power Successfully Completes Helical Coil Steam Generator Testing Activities
Business Wire - Tue Feb 25, 7:02AM CST
NuScale Power, LLC announced today that it recently successfully completed its helical coil steam generator (HCSG) testing activities at the SIET S.p.A. (SIET) facilities in Piacenza, Italy, and that during that same time period, the U.S. Nuclear Regulatory Commission (NRC) conducted a successful quality assurance (QA) inspection of the testing activities. The result of the inspection was a rare outcome in that the NRC concluded with no findings, observations, violations, recommendations or non-conformances identified.
Contact Dermatitis - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxk6vr/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2013" report to their offering. 'Contact Dermatitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contact Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contact Dermatitis. Scope - A snapshot of the global therapeutic scenario for Contact Dermatitis. - A review of the Contact Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contact Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Contact Dermatitis Overview Therapeutics Development Pipeline Products for Contact Dermatitis - Overview Pipeline Products for Contact Dermatitis - Comparative Analysis Contact Dermatitis - Therapeutics under Development by Companies Contact Dermatitis - Pipeline Products Glance Clinical Stage Products Early Stage Products Contact Dermatitis - Products under Development by Companies Contact Dermatitis - Companies Involved in Therapeutics Development Contact Dermatitis - Therapeutics Assessment Drug Profiles MRX-6 - Drug Profile RTU-1096 - Drug Profile MAM-06.301 - Drug Profile AN-3485 - Drug Profile HPT-721 - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned R-Tech Ueno, Ltd. Marinomed Biotechnologie GmbH Anacor Pharmaceuticals, Inc. Celsus Therapeutics Plc Hapten Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/hxk6vr/contact About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
